S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
Karen W.L. Yee,Karen W.L. Yee,Jorge E. Cortes,Alessandra Ferrajoli,Guillermo Garcia-Manero,Srdan Verstovsek,William G. Wierda,Deborah A. Thomas,Stefan Faderl,Ivan King,Susan O'Brien,Sima Jeha,Michael Andreeff,Ann Cahill,Mario Sznol,Francis J. Giles +15 more
TL;DR: The study was amended to include an ara-C dose level of 600mg/m2/day, no DLTs occurred in seven patients treated at this dose level, and the recommended phase II regimen is Triapine 105 mg/m 2/day followed by ara -C 600 mg/ m2/ day for 5 consecutive days every 3-6 weeks.
Journal ArticleDOI
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia
Farhad Ravandi,Jorge E. Cortes,Zeev Estrov,Deborah A. Thomas,Francis J. Giles,Yang O. Huh,Sherry Pierce,Susan O'Brien,Stefan Faderl,Hagop M. Kantarjian +9 more
TL;DR: CD56 expression in ALL is uncommon but may predict a higher risk for central nervous system (CNS) disease, and could be used in combination with other high-risk features to design a risk-oriented approach to CNS prophylaxis.
Journal ArticleDOI
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia
Paolo Strati,Hagop M. Kantarjian,D. A. Thomas,Susan O'Brien,Sergej Konoplev,Jeffrey L. Jorgensen,Raja Luthra,Lynne Abruzzo,Elias J. Jabbour,Alfonso Quintás-Cardama,Gautam Borthakur,Stefan Faderl,Farhad Ravandi,Jorge E. Cortes +13 more
TL;DR: Chronic myeloid leukemia (CML) may progress to blast phase (BP) at the rate of 1% to 1.5% per year and with the use of single‐agent tyrosine kinase inhibitors, median overall survival ranges between 7 and 11 months.
Journal ArticleDOI
Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia.
Steven M. Kornblau,Yihua Qiu,Nianxiang Zhang,Neera Singh,Stefan Faderl,Alessandra Ferrajoli,Heather York,Amina A. Qutub,Kevin R. Coombes,Dennis K. Watson +9 more
TL;DR: The FLI 1 level was not predictive of remission attainment, but patients with low or high FLI1 expression had shorter remission duration and overall survival.
Journal ArticleDOI
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Jorge E. Cortes,Hagop M. Kantarjian,Maher Albitar,Deborah A. Thomas,Stefan Faderl,Charles Koller,Guillermo Garcia-Manero,Francis J. Giles,Michael Andreeff,Susan O'Brien,Michael J. Keating,Elihu H. Estey +11 more
TL;DR: This study was designed to investigate the potential role of Th in the treatment of patients with AML and MDS and the possible role of a non–ara‐C‐containing regimen.